Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy looking at “disrupting” the cancer treatment market

Nicolas Serandour, chief operating officer (COO) and chief finance officer (CFO) Advanced Oncotherapy (LON:AVO), says the firm is looking at “disrupting the market” with its proton cancer treatment technology.

Serandour says: “We are in the business of treating cancer through radiotherapy but we are using – not X rays – but proton particles”.

The company is developing its cancer treating proton LIGHT proton therapy system, which accelerates protons to levels seen in previous machines but in a unit that is smaller and between a quarter and a fifth of the cost.

 “X rays are great at killing tumours but unfortunately because they are very light particles that are difficult to control, they also hit the tissue before and after the tumour,” he adds, noting that protons can attack the tumour without affecting the healthy tissue, but have, until now, been seen as too expensive by hospitals.

Meet Bluerock Diamonds Plc, Rambler Metals and Mining PLC, Touchstone Exploration Inc and Stratex International plc at our event, London , 19 June 2018. Register here »
View full AVO profile View Profile

Advanced Oncotherapy Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use